

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 1

of 9

Application Number	10/581,106
Filing Date	May 31, 2006
First Named Inventor	Judith A. Fox
Art Unit	1642
Examiner Name	Unassigned

Attorney Docket Number GC822-US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
	A1	US- 4,458,066	07/03/1984	Caruthers et al.	
	A2	US- 4,522,811	06/11/1985	Eppstein et al.	
	A3	US- 4,675,187	06/23/1987	Konishi et al.	
	A4	US- 4,711,845	12/08/1987	Gelfand et al.	
	A5	US- 4,975,278	12/04/1990	Senter et al.	
	A6	US- 5,711,944	01/27/1998	Gilbert et al.	
	A7	US- 5,766,883	06/16/1998	Ballance et al.	
	A8	US- 5,773,435	06/30/1998	Kadow et al.	
	A9	US- 5,843,440	12/01/1998	Pouletty et al.	
	A10	US- 60/388,387	12/24/2003	Schellenberger	
	A11	US- 2002/0142359	10/03/2002	Copley, et al.	
	A12	US- 10/170,729	03/13/2003	Edwards et al.	
	A13	US- 10/022,073	04/10/2003	Chen et al.	
	A14	US- 09/954,385	05/29/2003	Aehle et al.	
	A15	US- 10/170,387	06/05/2003	Murray	
	A16	US- 10/022,097	08/07/2003	Schellenberger	
	A17	US- 60/562,386	11/24/2005	Harding et al.	
	A18	US- 60/636,002	11/24/2005	Harding et al.	
	A19	US- 6,835,550	12/28/2004	Estell et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ "Number ⁴ " Kind Code ⁵ (if known)				
	B1	EP 0 196 864 A2	10/08/1986	Cetus Corporation		
	B2	WO 00/24782 A2	05/04/2000	Amgen Inc.		
	B3	WO 03/105757 A2	12/24/2003	Genencor International		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/581,106
		Filing Date	May 31, 2006
		First Named Inventor	Judith A. Fox
		Art Unit	1642
		Examiner Name	Unassigned
Sheet	2	of	9
		Attorney Docket Number	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO				Application Number	10/581,106
				Filing Date	May 31, 2006
				First Named Inventor	Judith A. Fox
				Art Unit	1642
				Examiner Name	Unassigned
Sheet	3	of	9	Attorney Docket Number	GC822-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ALTSCHUL, S.F., et al. "Basic local alignment search tool." J. Mol. Biol., 215(3): 403-410, 1990.	
	C2	ALTSCHUL, S.F., et al. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs." Nucleic Acids Res., 25(17): 3389-3402, 1997.	
	C3	**AUSUBEL, et al., eds., Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, 1989.	
	C4	BAGSHAWE, K.D., et al. "Developments with targeted enzymes in cancer therapy." Current Opinion in Immunology 11(5): 579-583, 1999.	
	C5	BEAUCAGE, S.L., et al., "Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis." Tetrahedron Lett., 22(20): 1859-1862, 1981.	
	C6	BENITO, A., et al. "Insertion of a 27 amino acid viral peptide in different zones of Escherichia coli β galactosidase: ..." FEMS Microbiology Letters, 123(1-2): 107-112, 1994.	
	C7	BOEHM, M.K., et al. "Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody ..." Biochemical Journal, 346: 519-528, 2000.	
	C8	BOLIVAR, F., et al. "Construction and characterization of new cloning vehicles. II. A multipurpose cloning system." Gene, 2(2): 95-113, 1977.	
	C9	BROACH, J.R. "Construction of high copy yeast vectors using 2- μ m circle sequences." Methods in Enzymology, 101: 307-325, 1983.	
	C10	BROWN, E.L., et al. "Chemical synthesis and cloning of a tyrosine tRNA gene." Methods in Enzymology, 68: 109-151, 1979.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/581,106
		Filing Date	May 31, 2006
		First Named Inventor	Judith A. Fox
		Art Unit	1642
		Examiner Name	Unassigned
Sheet 4	of 9	Attorney Docket Number	GC822-US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C11	CHANG, A., et al. "Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase." Nature, 275: 617-624, 1978.		
	C12	CHANG, M., et al. "The roles of inoleglycerol phosphate and the TrpI protein in the expression of trpBA from ..." Nucleic Acids Research, 18(4): 979-988, 1990.		
	C13	CHRISTOFIDOU-SOLOMIDOU, M., et al. "Immunotargeting of glucose oxidase to endothelium in vivo causes" Am J Physiol Lung Cell Mol Physiol, 278(4): L794-L805, 2000.		
	C14	CLARKE, L., et al. "Selection procedure for isolation of centromere DNAs from Saccharomyces cerevisiae." Methods in Enzymology, 101: 300-307, 1983.		
	C15	CLEWELL, D.B. "Nature of Col E1 Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol." J. Bacteriol., 110(2): 667-676, 1972.		
	C16	CLEWELL, D.B., et al. "Supercoiled circular DNA-protein complex in Escherichia coli: purification and induced ..." Proc. Natl. Acad. Sci. USA, 62(4): 1159-1166, 1969.		
	C17	COHEN, S.N., et al. "Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia ..." Proc. Natl. Acad. Sci. USA, 69(8): 2110-2114, 1972.		
	C18	**Cruz, et al., (eds), "Tissue Culture," Academic Press, 1973.		
	C19	DENNY, W.A. "Prodrug strategies in cancer therapy." Eur. J. of Med. Chem., 36 (7-8): 577-595, 2001.		
	C20	DEPICKER, A., et al. "Nopaline synthase: transcript mapping and DNA sequence." Journal of Molecular and Applied Genetics, 1(6): 561-573, 1982.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/581,106
		Filing Date	May 31, 2006
		First Named Inventor	Judith A. Fox
		Art Unit	1642
		Examiner Name	Unassigned
Sheet	5	of	9
		Attorney Docket Number	GC822-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	FIERS, W., et al. "Complete nucleotide sequence of SV40 DNA." Nature, 273(5658): 113-120, 1978.	
	C22	FRANCIS, R.J., et al. "A phase 1 trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal ..." Br. J. Cancer, 87(6): 600-607, 2002.	
	C23	FRANKEL, A., et al. "Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated ..." Clinical Cancer Research 6(9): 3719-3728, 2000.	
	C24	GOEDDEL, D.V., et al. "Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone." Nature, 281: 544-548, 1979.	
	C25	GOEDDEL, D.V., et al. "Synthesis of human fibroblast interferon by E. coli." Nucl. Acids Res., 8(18): 4057-4074, 1980.	
	C26	GOLD, P., et al. "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and ..." J Exp Med., 121(3): 439-462, 1965.	
	C27	GOODCHILD, J. "Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties." Bioconjug. Chem., 1(3): 165-87, 1990.	
	C28	GRAHAM, F.L., et al. "A new technique for the assay of infectivity of human adenovirus 5 DNA." Virology, 52(2): 456-467, 1973.	
	C29	HESS, B., et al. "Cooperation of glycolytic enzymes." Advances in Enzyme Regulation, 7: 149-167, 1968.	
	C30	HITZEMAN, R.A., et al. "Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological ..." J. Biol. Chem., 255(24): 12073-12080, 1980.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known	
Substitute for form 1449/PTO				Application Number	10/581,106
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Filing Date	May 31, 2006
				First Named Inventor	Judith A. Fox
				Art Unit	1642
				Examiner Name	Unassigned
Sheet	6	of	9	Attorney Docket Number	GC822-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C31	HOLLAND, M.J., et al. "Isolation and identification of yeast messenger ribonucleic acids coding for enolase..." Biochemistry, 17(23): 4900-4907, 1978.	
	C32	HOLLAND, M.J., et al. "The primary structures of two yeast enolase genes. Homology between the 5' noncoding flanking regions ..." J. Biol. Chem., 256(3): 1385-1395, 1981.	
	C33	HSIAO, C.-L., et al. "High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene." Proc. Natl. Acad. Sci. USA, 76(8): 3829-3333, 1979.	
	C34	KERR, D.E., et al. "Development and activities of a new melphalan prodrug designed for tumor-selective activation." Bioconjugate Chemistry, 9(2): 255-259, 1998.	
	C35	MARGOLIN, A.L., et al. "Substrate specificity of penicillin amidase from E. coli." Biochim. Biophys. Acta., 616(2): 283-289, 1980.	
	C36	MAXAM, A.M., et al. "Sequencing end-labeled DNA with base-specific chemical cleavages." Methods in Enzymology, 65(1): 499-560, 1980.	
	C37	MCDONAGH, C.F., et al. "Improved Yield and Stability of L49-sFv-β-Lactamase, a Single-Chain Antibody Fusion Protein for ..." Bioconjugate Chemistry, 14(5): 860-869, 2003.	
	C38	**MELTON, et al., Enzyme-Prodrug Strategies for Cancer Therapy Kluwer Academic/Plenum Publishers, New York, 1999	
	C39	MESSING, J., et al. "A system for shotgun DNA sequencing." Nucl. Acids Res., 9(2): 309-321, January 24, 1981.	
	C40	MILLER, D.W., et al. "An Insect Baculovirus Host-Vector ..." In Genetic Engineering: Principles and Methods, Setlow et al. (eds.), 8: 277-298; New York: Plenum Press, 1986.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number 10/581,106			
		Filing Date May 31, 2006			
		First Named Inventor Judith A. Fox			
		Art Unit 1642			
		Examiner Name Unassigned			
Sheet	7	of	9	Attorney Docket Number	GC822-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C41	NAPOLITANO, E.W., et al. "Glubodies: randomized libraries of glutathione transferase enzymes." Chemistry & Biology, 3(5): 359-367, 1996.	
	C42	NARANG, S.A., et al. "Improved phosphotriester method for the synthesis of gene fragments." Meth. Enzymol., 68: 90-98, 1979.	
	C43	NICULESCU-DUVAZ, I., et al. "Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)." Anti-Cancer Drug Design, 14(6): 517-538, 1999.	
	C44	**SAMBROOK, et al., (eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989.	
	C45	SANGER, F., et al. "DNA Sequencing with Chain-Terminating Inhibitors." Proc. Natl. Acad. Sci. USA, 74(12): 5463-5467, 1977.	
	C46	SHAW, C.H., et al. "A general method for the transfer of cloned genes to plant cells." Gene, 23(3): 315-330, 1983.	
	C47	SHIMATAKE, H., et al. "Purified λ regulatory protein cII positively activates promoters for lysogenic development." Nature ,292(5819): 128-132, 1981.	
	C48	SMITH, J.W., et al. "Protein Loop Grafting to Construct a Variant of Tissue-type Plasminogen Activator That Binds Platelet ..." J. Biol. Chem., 270(51): 30486-30490, 1995.	
	C49	STELLA, V.J., et al. "Prodrugs: A Chemical Approach to Targeted ..." In Directed Drug Delivery, Borchardt et al. (eds.), pp. 247-267. Clifton, NJ: Humana Press, 1985.	
	C50	STICKLER, M., et al. "Human population-based identification of CD4+ T-cell peptide epitope determinants." Journal of Immunological Methods, 281(1-2): 95-108, 2003.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/581,106
				Filing Date	May 31, 2006
				First Named Inventor	Judith A. Fox
				Art Unit	1642
				Examiner Name	Unassigned
Sheet	8	of	9	Attorney Docket Number	GC822-US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C51	STINCHCOMB, D.T., et al. "Isolation and characterisation of a yeast chromosomal replicator." Nature, 282(5734): 39-43, 1979.		T ²
	C52	THOMSON, K.S., et al. "Version 2000: the new β -lactamases of Gram-negative bacteria at the dawn of the new millennium." Microbes and Infection, 2(10): 1225-1235, 2000.		
	C53	TORCHILIN, V.P. "Drug targeting." European Journal of Pharmaceutical Sciences, 11(Supplement 2): S81-S91, 2000.		
	C54	TROUET, A., et al. "A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal..." Proc. Natl. Acad. Sci. USA, 79(2): 1982.		
	C55	TSCHUMPER, G., et al. "Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene." Gene, 10(2): 157-166, 1980.		
	C56	UMEMOTO, N., et al. "Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an ..." Int J Cancer, 43(4): 677-684, 1989.		
	C57	VAN SOLINGEN, P., et al. "Fusion of yeast spheroplasts." J. Bacteriol., 130(2): 946-947, 1977.		
	C58	VAUGHN, D.E., et al. "Structural basis of pH-dependent antibody binding by the neonatal Fc receptor." Structure, 6(1): 63-73, 1998.		
	C59	WILMAN, D.E., "Prodrugs in cancer chemotherapy." Biochemical Society Transactions 14(2): 375-382, 1986.		
	C60	XU, G., et al. "Strategies for Enzyme/Prodrug Cancer Therapy." Clin. Cancer Res., 7(11): 3314-3324, 2001.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/581,106
				Filing Date	May 31, 2006
				First Named Inventor	Judith A. Fox
				Art Unit	1642
				Examiner Name	Unassigned
Sheet	9	of	9	Attorney Docket Number	
GC822-US					

NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.